TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15513446

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with verteporfin (Visudyne®, Novartis AG) combined with feeder vessel treatment (FVT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) with verteporfin (Visudyne®, Novartis AG)
Number of subjects: 0
Study: 9467516

Group type: EXPERIMENTAL
Intervention: Stresst'er ergometer
Number of subjects: 94

Group type: COMPARATOR
Intervention: Treadmill testing
Number of subjects: 94
Study: 7941947

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) insertion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laryngoscopy and Tracheal Intubation
Number of subjects: 40
Study: 3328285

Group type: EXPERIMENTAL
Intervention: Sucralfate (S)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Sucralfate + Cimetidine (S + C)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Cimetidine (C)
Number of subjects: 230
Study: 31773734

Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention (TranS-C)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Psychoeducation about sleep and health (PE)
Number of subjects: 176
Study: 30098269

Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 47

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 47
Study: 28271568

Group type: EXPERIMENTAL
Intervention: Ziziphus jujube fruit (ZJF) infusion (10 g/100 mL boiling water) three times/day before main meals for 12 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Balanced diet
Number of subjects: 116
Study: 26180244

Group type: EXPERIMENTAL
Intervention: Dairy-based meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Soy oil-based meal
Number of subjects: 16
Study: 24124681

Group type: EXPERIMENTAL
Intervention: HPP group (hemi-portal vein preserved inflow occlusion)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MPV group (main portal vein inflow occlusion)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: HHV group (hemi-hepatic vascular inflow occlusion)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MPV group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: HHV group
Number of subjects: 180
Study: 20528210

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol-drospirenone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Flutamide-metformin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combined treatment with ethinylestradiol-drospirenone and flutamide-metformin
Number of subjects: 41
Study: 18931625

Group type: EXPERIMENTAL
Intervention: Intermittent treatment (IT) - fixed 8‐week off, 8‐week on regimen
Number of subjects: 403

Group type: COMPARATOR
Intervention: Continuous treatment (CT) - maintain current treatment strategy
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Intermittent treatment (IT)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Continuous treatment (CT)
Number of subjects: 403
Study: 16820341

Group type: EXPERIMENTAL
Intervention: CGA (140 mg/day) from green coffee bean extract
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 14968473

Group type: EXPERIMENTAL
Intervention: 100 mg/day of elemental zinc for 3 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10979549

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study: 8968239

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 437

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 437

Group type: COMPARATOR
Intervention: Medical management of miscarriage
Number of subjects: 437
Study: 1590494

Group type: EXPERIMENTAL
Intervention: Focused cognitive therapy for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Brief supportive psychotherapy for 8 weeks (Control)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Crossover to focused cognitive therapy for 12 weeks
Number of subjects: 33
Study: 6084394

Group type: EXPERIMENTAL
Intervention: 2.5% phenylpropanolamine (PPA) solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 40
Study: 30630581

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 108

Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 108
Study: 28841508

Group type: EXPERIMENTAL
Intervention: Movement Control & Strengthening group (MC&S group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Strengthening group (S group)
Number of subjects: 34
Study: 26515839

Group type: EXPERIMENTAL
Intervention: Twice-weekly targeted ultraviolet B phototherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Once-weekly targeted ultraviolet B phototherapy
Number of subjects: 60
Study: 24229746

Group type: EXPERIMENTAL
Intervention: Memantine (flexible dose 5-20 mg/d, all reaching 20 mg/d)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 31
Study: 21557134

Group type: EXPERIMENTAL
Intervention: Gain-framed, targeted materials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care materials (control)
Number of subjects: 0
Study: 19477434

Group type: EXPERIMENTAL
Intervention: Experiential avoidance (EA)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Depression
Number of subjects: 81
Study: 17060222

Group type: EXPERIMENTAL
Intervention: Visited group (systematic on-site visits)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non-visited group (no systematic on-site visits)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Visited group
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non-visited group
Number of subjects: 69
Study: 15022581

Group type: EXPERIMENTAL
Intervention: Dexamethasone for five days (12 mg single dose)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexamethasone less than five days (12 mg single dose)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 150
Study: 10964582

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (Neoral), administered once, dosage not specified
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo, administered once, matching CsA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (Neoral)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8619212

Group type: EXPERIMENTAL
Intervention: Endoscopic tension-free hernia repair
Number of subjects: 120

Group type: COMPARATOR
Intervention: Open tension-free hernia repair
Number of subjects: 120
Study: 1308265

Group type: EXPERIMENTAL
Intervention: Cefazolin preoperatively
Number of subjects: 228

Group type: COMPARATOR
Intervention: Amoxicillin + Gentamycin postoperatively
Number of subjects: 228
Study: 3872001

Group type: EXPERIMENTAL
Intervention: Alcuronium 0.25 mg X kg b.w.‐1 with high-dose fentanyl
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg X kg b.w.‐1 with high-dose fentanyl
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Alcuronium 0.25 mg X kg b.w.‐1 with balanced anaesthesia
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.05 mg X kg b.w.‐1 + alcuronium 0.125 mg X kg b.w.‐1
Number of subjects: 92

Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg X kg b.w.‐1
Number of subjects: 92

Group type: COMPARATOR
Intervention: Alcuronium 0.25 mg X kg b.w.‐1
Number of subjects: 92
Study: 30628743

Group type: EXPERIMENTAL
Intervention: Mendelian randomisation (MR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 28840591

Group type: EXPERIMENTAL
Intervention: Dedicated bifurcation BiOSS® stents
Number of subjects: 445

Group type: COMPARATOR
Intervention: Regular drug-eluting stents (rDES)
Number of subjects: 445
Study: 27004662

Group type: EXPERIMENTAL
Intervention: 15m straight line
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FIG8
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5m trial
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 to 30 strides
Number of subjects: 24
Study: 25215468

Group type: EXPERIMENTAL
Intervention: Amino acid supplementation (arginine, glutamine, HMB) twice daily for 2 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 22929437

Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1 (GLP-1)
Number of subjects: 9
Study: 20059663

Group type: EXPERIMENTAL
Intervention: Physical therapy treatment (manual therapy, biofeedback, electrical stimulation, dilator insertions, and home exercises) for women with PVD after 8 sessions
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (women without PVD)
Number of subjects: 22
Study: 17512098

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 23 valent pneumococcal vaccine
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 23 valent pneumococcal vaccine
Number of subjects: 254

Group type: COMPARATOR
Intervention: Subcutaneous injection compared to intramuscular injection
Number of subjects: 254

Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 254

Group type: COMPARATOR
Intervention: Pre‐vaccination antibody titres >1 microg/ml
Number of subjects: 254

Group type: COMPARATOR
Intervention: Female gender with subcutaneous injection
Number of subjects: 254
Study: 15470483

Group type: EXPERIMENTAL
Intervention: Low-salt intake
Number of subjects: 114

Group type: COMPARATOR
Intervention: High-salt intake
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Low-sodium phase
Number of subjects: 114

Group type: COMPARATOR
Intervention: High-sodium phase
Number of subjects: 114
Study: 11824861

Group type: EXPERIMENTAL
Intervention: COER-24 verapamil 240 mg/day titrated to 360 mg/day
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: enalapril 10 mg/day titrated to 20 mg/day
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: losartan 50 mg/day titrated to 100 mg/day
Number of subjects: 406

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 406
Study: 11008892

Group type: EXPERIMENTAL
Intervention: 2 mg b.i.d. oral nilvadipine for 4 weeks
Number of subjects: 12
Study: 8618108

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid (AMC) 500/125mg tid for 7 days
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cefetamet pivoxil (CAT) 500mg bid for 7 days
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid (AMC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cefetamet pivoxil (CAT)
Number of subjects: 180
Study: 2127045

Group type: EXPERIMENTAL
Intervention: Xylitol infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucose infusion
Number of subjects: 20
Study: 6101610

Group type: EXPERIMENTAL
Intervention: Psychotropic substances (initial standard dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30644628

Group type: EXPERIMENTAL
Intervention: Intranasal 1.4 mg naloxone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intramuscular 0.8 mg naloxone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intranasal 1.4 mg naloxone (two doses)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intranasal 1.4 mg naloxone vs Intramuscular 0.8 mg naloxone
Number of subjects: 22
Study: 28507370

Group type: EXPERIMENTAL
Intervention: Dynamic Soft Tissue Mobilization (DSTM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Passive Stretching (PS)
Number of subjects: 120
Study: 26044854

Group type: EXPERIMENTAL
Intervention: Exposure to 4000 pollen grains/m(3) of Dactylis glomerata pollen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clean air (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grass pollen exposure
Number of subjects: 0
Study: 23973868

Group type: EXPERIMENTAL
Intervention: Presence of Papillary Muscle Infarction (PapMI)
Number of subjects: 738
Study: 21243655

Group type: EXPERIMENTAL
Intervention: Modified sleep hygiene intervention (infant proximity, noise masking, and dim lighting)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 240
Study: 19864452

Group type: EXPERIMENTAL
Intervention: Saxagliptin (2.5 mg) plus TZD
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Saxagliptin (5 mg) plus TZD
Number of subjects: 565

Group type: COMPARATOR
Intervention: Placebo (PBO) plus TZD
Number of subjects: 565
Study: 17925592

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg daily
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 12007948

Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) brachytherapy
Number of subjects: 0
Study: 10728939

Group type: EXPERIMENTAL
Intervention: alpha‐streptococcal spray treatment
Number of subjects: 342

Group type: COMPARATOR
Intervention: placebo spray treatment
Number of subjects: 342
Study: 7536871

Group type: EXPERIMENTAL
Intervention: Filgrastim treatment for neutrophil recovery
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study: 2027357

Group type: EXPERIMENTAL
Intervention: Dexamethasone and cefotaxime (n = 52)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Cefotaxime plus placebo (n = 49)
Number of subjects: 101
Study: 6161557

Group type: EXPERIMENTAL
Intervention: 10% hydroxyethylstarch (LMW‐HES)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 10% dextran 40 (followed by dextran 60 intraoperatively)
Number of subjects: 16
Study: 31025259

Group type: EXPERIMENTAL
Intervention: In ovo injection of 1 × 10^9 CFU B. bifidum
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: In ovo injection of 1 × 10^7 CFU B. bifidum
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: In ovo injection of 1 × 10^9 CFU B. longum
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: In ovo injection of 1 × 10^7 CFU B. longum
Number of subjects: 300

Group type: COMPARATOR
Intervention: Intact (without injection) control group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Vehicle-injected (sterile distilled water) control group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: In ovo injection of bifidobacteria strains
Number of subjects: 300
Study: 30126448

Group type: EXPERIMENTAL
Intervention: Minocycline for 8 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Minocycline for 16 weeks
Number of subjects: 32
Study: 28057659

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 at a dose of 108 colony-forming units, orally, twice daily during antibiotic treatment
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo, identically appearing, orally, twice daily during antibiotic treatment
Number of subjects: 250
Study: 25527751

Group type: EXPERIMENTAL
Intervention: High-fat meal with added protein (61.5% of energy from fat; 51.1 ± 7.9 g of protein; 191.9 ± 9.9 kcal added)
Number of subjects: 9

Group type: COMPARATOR
Intervention: High-fat meal without added protein
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-fat meal with added protein
Number of subjects: 9
Study: 23207175

Group type: EXPERIMENTAL
Intervention: AcrySof SA60AT lens
Number of subjects: 300

Group type: COMPARATOR
Intervention: Tecsoft Flex lens
Number of subjects: 300
Study: 21505892

Group type: EXPERIMENTAL
Intervention: L-thyroxin (L-T4) therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 27
Study: 18486783

Group type: EXPERIMENTAL
Intervention: Open reposition and internal fixation of displaced or dislocated fractures (Classes II to V)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Closed treatment of nondisplaced, nondislocated fractures (Classes I and VI)
Number of subjects: 24
Study: 16841627

Group type: EXPERIMENTAL
Intervention: Pregabalin 400 mg/day
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg/day
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 12920975

Group type: EXPERIMENTAL
Intervention: Volume Guarantee (VG) set at 5 ml/Kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Volume Guarantee (VG) set at 3 ml/Kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Volume Guarantee (VG)
Number of subjects: 0
Study: 9929021

Group type: EXPERIMENTAL
Intervention: PTAS
Number of subjects: 42

Group type: COMPARATOR
Intervention: PTA
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Secondary stenting after PTA failure
Number of subjects: 42
Study: 7498858

Group type: EXPERIMENTAL
Intervention: Combination treatment of verapamil retard (240 mg) and hydrochlorothiazide (12.5 mg)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Monotherapy with verapamil or hydrochlorothiazide
Number of subjects: 173
Study: 2258338

Group type: EXPERIMENTAL
Intervention: Pefloxacin (400 mg twice daily, orally)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Ceftazidime (2 g twice daily, iv)
Number of subjects: 170
Study: 6780235

Group type: EXPERIMENTAL
Intervention: Proxicromil (18 mg twice per day for the first 3 weeks, then 18 mg four times per day for the next 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (corresponding placebo for a final period of three weeks)
Number of subjects: 0
Study: 31904166

Group type: EXPERIMENTAL
Intervention: 3D printed model
Number of subjects: 118

Group type: COMPARATOR
Intervention: Half skull
Number of subjects: 118
Study: 31274260

Group type: EXPERIMENTAL
Intervention: RECOGNeyes game with eye-tracker for 3 weeks (3 times/week)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mouse control
Number of subjects: 28
Study: 29191850

Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg daily)
Number of subjects: 864

Group type: COMPARATOR
Intervention: Control (no statins)
Number of subjects: 864
Study: 26809868

Group type: EXPERIMENTAL
Intervention: IgG4-guided exclusion diet (excluding four food types with the highest antibody titers for 4 weeks)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham group (excluding four foods with the lowest antibody titers)
Number of subjects: 76
Study: 24015807

Group type: EXPERIMENTAL
Intervention: Bacterial agency language
Number of subjects: 719

Group type: COMPARATOR
Intervention: Human agency language
Number of subjects: 719
Study: 23244537

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FO) 1 g twice a day for 120 days
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (mineral oil) 1 g twice a day for 120 days
Number of subjects: 160
Study: 20645937

Group type: EXPERIMENTAL
Intervention: SCIT with depigmented-polymerized mixed tree pollen extract
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 17932317

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (20 mg/kg/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sulfonylureas
Number of subjects: 64
Study: 15533545

Group type: EXPERIMENTAL
Intervention: Behavioral counseling (delivered in two 15-min sessions with written material)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Nutritional education
Number of subjects: 271
Study: 12045168

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 630

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 630

Group type: COMPARATOR
Intervention: No PFO
Number of subjects: 630

Group type: COMPARATOR
Intervention: Small PFO
Number of subjects: 630

Group type: COMPARATOR
Intervention: Large PFO
Number of subjects: 630

Group type: COMPARATOR
Intervention: Isolated PFO
Number of subjects: 630

Group type: COMPARATOR
Intervention: PFO with atrial septal aneurysm
Number of subjects: 630
Study: 10407789

Group type: EXPERIMENTAL
Intervention: Newborn metabolic screening using tandem mass spectrometry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian synthesis approach
Number of subjects: 0
Study: 7599015

Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Erythromycin 1.5 g
Number of subjects: 40
Study: 29570454

Group type: EXPERIMENTAL
Intervention: Repeat/second cesarean with ultrasound-guided intervention (Int-G)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Second cesarean utilizing the usual procedure (CS2-G)
Number of subjects: 124
Study: 28851407

Group type: EXPERIMENTAL
Intervention: Second 1000-ml fluid bolus (standard care)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance rate fluid only with early commencement of a vasopressor infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 25103924

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 23143075

Group type: EXPERIMENTAL
Intervention: Online support group for parents of children with autism spectrum disorders (4-month duration)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Online support group for parents of children with autism spectrum disorders
Number of subjects: 45
Study: 22021620

Group type: EXPERIMENTAL
Intervention: Raltegravir treatment intensification
Number of subjects: 23

Group type: COMPARATOR
Intervention: No treatment augmentation (Control)
Number of subjects: 23
Study: 18654778

Group type: EXPERIMENTAL
Intervention: Elastic intramedullary nailing (EIN)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dynamic skeletal traction spica casting (DSTSC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups (EIN and DSTSC)
Number of subjects: 51
Study: 16466830

Group type: EXPERIMENTAL
Intervention: Healthy/weight loss foods
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Unhealthy/weight gain foods
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pre- to post-weight loss treatment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Higher baseline BMI
Number of subjects: 55
Study: 14970855

Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 0
Study: 11733695

Group type: EXPERIMENTAL
Intervention: Contralateral precues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipsilateral precues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized task presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocked task presentation
Number of subjects: 0
Study: 9223393

Group type: EXPERIMENTAL
Intervention: 5 mg glimepiride daily for 7 days and 10 mg prior to a hyperglycaemic clamp
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14